340 related articles for article (PubMed ID: 23727126)
1. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor.
Hsu SH; Yu B; Wang X; Lu Y; Schmidt CR; Lee RJ; Lee LJ; Jacob ST; Ghoshal K
Nanomedicine; 2013 Nov; 9(8):1169-80. PubMed ID: 23727126
[TBL] [Abstract][Full Text] [Related]
2. miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker.
Li F; Wang F; Zhu C; Wei Q; Zhang T; Zhou YL
Int J Nanomedicine; 2018; 13():2295-2307. PubMed ID: 29713162
[TBL] [Abstract][Full Text] [Related]
3. Effect of Tumor Suppressor MiR-34a Loaded on ZSM-5 Nanozeolite in Hepatocellular Carcinoma: In Vitro and In Vivo Approach.
Salah Z; Abd El Azeem EM; Youssef HF; Gamal-Eldeen AM; Farrag AR; El-Meliegy E; Soliman B; Elhefnawi M
Curr Gene Ther; 2019; 19(5):342-354. PubMed ID: 31701846
[TBL] [Abstract][Full Text] [Related]
4. Sphk2 RNAi nanoparticles suppress tumor growth via downregulating cancer cell derived exosomal microRNA.
Liang J; Zhang X; He S; Miao Y; Wu N; Li J; Gan Y
J Control Release; 2018 Sep; 286():348-357. PubMed ID: 30077738
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma.
Komoll RM; Hu Q; Olarewaju O; von Döhlen L; Yuan Q; Xie Y; Tsay HC; Daon J; Qin R; Manns MP; Sharma AD; Goga A; Ott M; Balakrishnan A
J Hepatol; 2021 Jan; 74(1):122-134. PubMed ID: 32738449
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma.
Makita Y; Murata S; Katou Y; Kikuchi K; Uejima H; Teratani M; Hoashi Y; Kenjo E; Matsumoto S; Nogami M; Otake K; Kawamata Y
Biochem Biophys Res Commun; 2017 Nov; 493(1):800-806. PubMed ID: 28843857
[TBL] [Abstract][Full Text] [Related]
7. Lipid Nanoparticle Systems for Enabling Gene Therapies.
Cullis PR; Hope MJ
Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
[TBL] [Abstract][Full Text] [Related]
8. Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets.
Zheng F; Liao YJ; Cai MY; Liu TH; Chen SP; Wu PH; Wu L; Bian XW; Guan XY; Zeng YX; Yuan YF; Kung HF; Xie D
PLoS Genet; 2015 Feb; 11(2):e1004873. PubMed ID: 25693145
[TBL] [Abstract][Full Text] [Related]
9. microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma.
Zhu C; Zhou R; Zhou Q; Chang Y; Jiang M
Life Sci; 2016 Dec; 166():34-40. PubMed ID: 27717846
[TBL] [Abstract][Full Text] [Related]
10. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
11. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations.
Wang X; Yu B; Ren W; Mo X; Zhou C; He H; Jia H; Wang L; Jacob ST; Lee RJ; Ghoshal K; Lee LJ
J Control Release; 2013 Dec; 172(3):690-8. PubMed ID: 24121065
[TBL] [Abstract][Full Text] [Related]
12. Loss of
Liu Y; Liu H; Yang L; Wu Q; Liu W; Fu Q; Zhang W; Zhang H; Xu J; Gu J
J Biol Chem; 2017 Feb; 292(8):3186-3200. PubMed ID: 28062574
[TBL] [Abstract][Full Text] [Related]
13. MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
Zhao P; Wu S; Cheng Y; You J; Chen Y; Li M; He C; Zhang X; Yang T; Lu Y; Lee RJ; He X; Xiang G
Nanomedicine; 2017 Nov; 13(8):2507-2516. PubMed ID: 28577837
[TBL] [Abstract][Full Text] [Related]
14. Lipid Nanoparticle-Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth.
Huang X; Magnus J; Kaimal V; Karmali P; Li J; Walls M; Prudente R; Sung E; Sorourian M; Lee R; Davis S; Yang X; Estrella H; Lee EC; Chau BN; Pavlicek A; Zabludoff S
Mol Cancer Ther; 2017 May; 16(5):905-913. PubMed ID: 28167506
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma.
Farra R; Grassi M; Grassi G; Dapas B
World J Gastroenterol; 2015 Aug; 21(30):8994-9001. PubMed ID: 26290628
[TBL] [Abstract][Full Text] [Related]
16. Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Liu L; Yang X; Li NF; Lin L; Luo H
Cell Cycle; 2019 Nov; 18(21):2939-2953. PubMed ID: 31522588
[No Abstract] [Full Text] [Related]
17. Ultrasound-Assisted miR-122-Loaded Polymeric Nanodroplets for Hepatocellular Carcinoma Gene Therapy.
Guo H; Xu M; Cao Z; Li W; Chen L; Xie X; Wang W; Liu J
Mol Pharm; 2020 Feb; 17(2):541-553. PubMed ID: 31876426
[TBL] [Abstract][Full Text] [Related]
18. ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma.
Jang JY; Lee YS; Jeon YK; Lee K; Jang JJ; Kim CW
Exp Mol Med; 2013 Jan; 45(1):e3. PubMed ID: 23306701
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer.
Lee HY; Mohammed KA; Kaye F; Sharma P; Moudgil BM; Clapp WL; Nasreen N
Int J Nanomedicine; 2013; 8():4481-94. PubMed ID: 24293999
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo.
He XX; Chang Y; Meng FY; Wang MY; Xie QH; Tang F; Li PY; Song YH; Lin JS
Oncogene; 2012 Jul; 31(28):3357-69. PubMed ID: 22056881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
